Royalty Pharma and Teva agree on $500M funding for TEV-‘408 development. TEV-‘408 shows promise for treating autoimmune conditions like vitiligo. Teva plans Phase 2b study for vitiligo to start in 2026. Teva expects stable earnings with mid-single-digit CAGR through 2030. S&P upgraded Teva's credit rating, indicating positive financial outlook.
Royalty Pharma commits up to $2 billion to Revolution Medicines for drug development. This financing may strengthen RPRX's market position and potential future revenues.
